Difference between revisions of "Part:BBa K4165150"

 
Line 5: Line 5:
 
Tau binding peptide targeting the PHF seed of Tau
 
Tau binding peptide targeting the PHF seed of Tau
  
−
<!-- Add more about the biology of this part here
+
 
 
===Usage and Biology===
 
===Usage and Biology===
 +
This part is derived from D-enantiomeric peptide its amino acid sequence is APTLLRLHSLGA, that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability.
  
 
<!-- -->
 
<!-- -->
Line 12: Line 13:
 
<partinfo>BBa_K4165150 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165150 SequenceAndFeatures</partinfo>
  
 +
 +
 +
 +
===Dry Lab===
 +
 +
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 +
APT were modeled by AlphaFold2, Apptest, ITASSER and RosettaFold. best model is obtained from AlphaFold2 and the model is shown below
 +
 +
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/apt.png" style="margin-left:200px;" alt="" width="500" /></p>
 +
</html>
 +
 +
                            Figure 1.: Predicted 3D structure of Synthetic peptide APT.
 +
 +
<p style=" font-weight: bold; font-size:13px;"> Table 1: Quality assessment parameters of TLKIVW model. </p>
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/apt-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 +
</html>
 +
 +
 +
===References===
 +
1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  

Revision as of 17:20, 5 October 2022


APT Peptide

Tau binding peptide targeting the PHF seed of Tau


Usage and Biology

This part is derived from D-enantiomeric peptide its amino acid sequence is APTLLRLHSLGA, that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]



Dry Lab

Modeling

APT were modeled by AlphaFold2, Apptest, ITASSER and RosettaFold. best model is obtained from AlphaFold2 and the model is shown below 


                            Figure 1.: Predicted 3D structure of Synthetic peptide APT.

Table 1: Quality assessment parameters of TLKIVW model.


References

1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.